Dantrolene ๐
๐ About
Always check the BNF link here for up-to-date prescribing information.
- ๐ Alternative to baclofen for reducing muscle tone and spasticity.
- ๐จ Specific role in treating malignant hyperthermia (MH) and neuroleptic malignant syndrome (NMS).
โ๏ธ Mechanism of Action
- Acts directly on skeletal muscle.
- Blocks calcium release from the sarcoplasmic reticulum.
- Impairs excitationโcontraction coupling โ muscle relaxation.
๐ฏ Indications
- Spasticity in neurological conditions (alternative when baclofen poorly tolerated or ineffective).
- Malignant hyperthermia (anaesthetic emergency) ๐.
- Neuroleptic malignant syndrome (antipsychotic emergency) โก.
๐ Dantrolene โ Dosing
| Indication |
Details |
| ๐ฆต Spasticity |
Dantrolene
Start: 25 mg BD, titrate slowly
Usual range: 25 mg BD โ up to 100 mg QDS
Route: PO / IV / IM
|
| ๐ฅ Malignant Hyperthermia / NMS |
Dantrolene
Initial: 2โ3 mg/kg IV
Then: 1 mg/kg IV, repeat if needed
Maximum: 10 mg/kg per course
โ ๏ธ Give via large vein โ extravasation can cause severe soft tissue injury
|
๐ Interactions
- Concurrent oestrogens may increase risk of hepatotoxicity.
- Use caution with other hepatotoxic drugs.
โ Contraindications
- Active or previous liver disease (risk of hepatotoxicity).
- Pregnancy (safety not established).
โ ๏ธ Side Effects
- Drowsiness, dizziness, weakness, vertigo ๐ต.
- GI upset: nausea, diarrhoea.
- Hepatotoxicity (dose-related, especially at >400 mg/day or with long-term use) โ ๏ธ.
- Photosensitivity reactions (rare).
๐ References
- BNF โ Dantrolene
- Oxford Handbook of Clinical Medicine.
- Anaesthesia textbooks โ malignant hyperthermia management.